AtheroGenics releases diabetes data

AtheroGenics has released Phase III trial data showing that the patients who did not have diabetes when beginning treatment and assigned to the AGI-1067 dosage group benefited by a 63 percent reduction in progression to new onset diabetes, compared to the patients receiving placebo. Release

Suggested Articles

After teaming up with other Big Pharmas to bolster antibiotics research, Pfizer is adding a new antibiotic prospect to its pipeline.

The oral direct-acting antiviral is set to enter a phase 3 trial in non-hospitalized patients early next year.

RA Capital 's 15-month old inaugural venture fund that has already seen 25% of its portfolio companies IPO or be acquired.